Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 290

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation

Open access
Salvesen, H. B., Carter, S. L., Mannelqvist, M., Dutt, A., Getz, G., Stefansson, I. M., Raeder, M. B., Sos, M. L., Engelsen, I. B., Trovik, J., Wik, E., Greulich, H., Bø, T. H., Jonassen, I., Thomas, R. K., Zander, T., Garraway, L. A., Øyan, A. M., Sellers, W. R., Kalland, K. H., Meyerson, M., Akslen, L. A., Beroukhim, R.·2009·Proceedings of the National Academy of Sciences

Abstract

Although 75% of endometrial cancers are treated at an early stage, 15% to 20% of these recur. We performed an integrated analysis of genome-wide expression and copy-number data for primary endometrial carcinomas with extensive clinical and histopathological data to detect features predictive of recurrent disease. Unsupervised analysis of the expression data distinguished 2 major clusters with strikingly different phenotypes, including significant differences in disease-free survival. To identify possible mechanisms for these differences, we performed a global genomic survey of amplifications, deletions, and loss of heterozygosity, which identified 11 significantly amplified and 13 significantly deleted regions. Amplifications of 3q26.32 harboring the oncogene PIK3CA were associated with poor prognosis and segregated with the aggressive transcriptional cluster. Moreover, samples with PIK3CA amplification carried signatures associated with in vitro activation of PI3 kinase (PI3K), a signature that was shared by aggressive tumors without PIK3CA amplification. Tumors with loss of PTEN expression or PIK3CA overexpression that did not have PIK3CA amplification also shared the PI3K activation signature, high protein expression of the PI3K pathway member STMN1, and an aggressive phenotype in test and validation datasets. However, mutations of PTEN or PIK3CA were not associated with the same expression profile or aggressive phenotype. STMN1 expression had independent prognostic value. The results affirm the utility of systematic characterization of the cancer genome in clinically annotated specimens and suggest the particular importance of the PI3K pathway in patients who have aggressive endometrial cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0806514106

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 31 references

Cited by

See all 290

Metadata

Authors
Salvesen, H. B., Carter, S. L., Mannelqvist, M., Dutt, A., Getz, G., Stefansson, I. M., Raeder, M. B., Sos, M. L., Engelsen, I. B., Trovik, J., Wik, E., Greulich, H., Bø, T. H., Jonassen, I., Thomas, R. K., Zander, T., Garraway, L. A., Øyan, A. M., Sellers, W. R., Kalland, K. H., Meyerson, M., Akslen, L. A., & Beroukhim, R.
Venue
Proceedings of the National Academy of Sciences
Published
2009-03-24
Volume
106
Issue
12
Pages
4834-4839
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2161640106
Cited by
290
References
31
FWCI
26.98
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. https://app.cochat.ai/papers/10.1073/pnas.0806514106
The paper
Salvesen, H. B., Carter, S. L., Mannelqvist, M., Dutt, A., Getz, G., Stefansson, I. M., Raeder, M. B., Sos, M. L., Engelsen, I. B., Trovik, J., Wik, E., Greulich, H., Bø, T. H., Jonassen, I., Thomas, R. K., Zander, T., Garraway, L. A., Øyan, A. M., Sellers, W. R., . . . Beroukhim, R. (2009). Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0806514106

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.